Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Express Scripts-Medco Merger Closes With No Divestitures Needed

This article was originally published in The Pink Sheet Daily

Executive Summary

The FTC voted in a split 3-1 vote to close its investigation and allow Express Scripts’ $29.1 billion acquisition of rival PBM Medco to proceed.

You may also be interested in...

FTC Scrutiny Of Profit Seeking In Drug Supply Chain In Fact-Finding Mode

Agency hears from experts on whether PBMs and group purchasing organizations operate under misaligned incentives.

Rite Aid To Gain Specialty Drug, Part D Platforms With PBM EnvisionRx

The drug store chain will purchase EnvisionRx, which serves over 21 million members and expects to manage 145 million pharmacy claims in 2015, for $2 billion in cash and stock.

Humana Weighing Drug Purchasing Change With PBM “Strategic Review”

The insurer is considering strategic options for its internal PBM, which manages more than 300 million drug claims for more than 9 million individuals, mainly in the Medicare space.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts